Compare Terumo Corp. with Similar Stocks
Dashboard
1
Low Debt Company with Strong Long Term Fundamental Strength
- Healthy long term growth as Net Sales has grown by an annual rate of 12.52%
- Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 36.60
- The company has been able to generate a Return on Capital Employed (avg) of 11.10% signifying high profitability per unit of total capital (equity and debt)
2
With a growth in Net Profit of 167.1%, the company declared Outstanding results in Jun 26
3
With ROE of 8.40%, it has a attractive valuation with a 2.16 Price to Book Value
4
Majority shareholders : FIIs
Stock DNA
Pharmaceuticals & Biotechnology
JPY 3,255,751 Million (Large Cap)
26.00
NA
0.00%
0.07
8.58%
2.05
Revenue and Profits:
Net Sales:
311,810 Million
(Quarterly Results - Jun 2026)
Net Profit:
70,426 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.93%
0%
-0.93%
6 Months
5.29%
0%
5.29%
1 Year
-11.58%
0%
-11.58%
2 Years
-14.76%
0%
-14.76%
3 Years
-49.17%
0%
-49.17%
4 Years
-48.9%
0%
-48.9%
5 Years
-59.07%
0%
-59.07%
Terumo Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.52%
EBIT Growth (5y)
13.81%
EBIT to Interest (avg)
39.80
Debt to EBITDA (avg)
0.19
Net Debt to Equity (avg)
-0.03
Sales to Capital Employed (avg)
0.62
Tax Ratio
23.61%
Dividend Payout Ratio
32.56%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
11.15%
ROE (avg)
8.48%
Valuation key factors
Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
2.16
EV to EBIT
18.30
EV to EBITDA
12.36
EV to Capital Employed
2.05
EV to Sales
3.15
PEG Ratio
8.74
Dividend Yield
NA
ROCE (Latest)
11.19%
ROE (Latest)
8.40%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 4 Foreign Institutions (0.02%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
311,810.00
300,320.00
3.83%
Operating Profit (PBDIT) excl Other Income
96,030.00
60,637.00
58.37%
Interest
1,476.00
1,527.00
-3.34%
Exceptional Items
0.00
0.00
Consolidate Net Profit
70,426.00
26,367.00
167.10%
Operating Profit Margin (Excl OI)
220.80%
113.90%
10.69%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 3.83% vs 1.24% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 167.10% vs -19.24% in Mar 2026
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
1,131,877.00
1,036,171.00
9.24%
Operating Profit (PBDIT) excl Other Income
280,118.00
264,471.00
5.92%
Interest
2,825.00
2,016.00
40.13%
Exceptional Items
-12,357.00
-24,728.00
50.03%
Consolidate Net Profit
135,914.00
116,978.00
16.19%
Operating Profit Margin (Excl OI)
163.20%
172.80%
-0.96%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 9.24% vs 12.40% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 16.19% vs 9.97% in Mar 2025
About Terumo Corp. 
Terumo Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






